Halozyme Therapeutics (HALO) Tops Q1 EPS by 5c, Revenues Beat; Offers FY21 EPS Mid-Point Guidance Above Consensus, FY21 Revs. Mid-Point Views Below Consensus

Go back to Halozyme Therapeutics (HALO) Tops Q1 EPS by 5c, Revenues Beat; Offers FY21 EPS Mid-Point Guidance Above Consensus, FY21 Revs. Mid-Point Views Below Consensus
Halozyme Therapeutics, Inc. (NASDAQ: HALO) Delayed: 41.14 -1.03 (2.44%)
Previous Close $42.17    52 Week High $18.39 
Open $42.10    52 Week Low $6.96 
Day High $42.13    P/E N/A 
Day Low $40.75    EPS $-0.58 
Volume 792,359